Myelodysplastic Syndromes (MDS)MDSNCT02775383
The National Myelodysplastic Syndromes (MDS) Study
An observational study of Myelodysplastic Syndromes (MDS), run by National Heart, Lung, and Blood Institute (NHLBI) at 281 sites in 2 countries.
Trial summary
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myelodysplastic Syndromes (MDS)
- What is being tested?
- Therapeutic
- How many people
- 2,115 participants
- Where
- 281 sitesin 2 countries
- Study dates
- 13 Jun 2016to 31 Dec 2025
- How long will I take part?
- 9 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with suspected MDS or MDS/MPN overlap disorder who are undergoing diagnostic workup and bone marrow assessments, and patients diagnosed with MDS within 6-months of enrollment and undergoing clinical evaluation and bone marrow assessments to confirm MDS or evaluate disease status
Who may be able to join
- Suspected (e.g., persistent unexplained cytopenia, circulating peripheral blasts etc.) MDS or MDS/MPN overlap disorders and undergoing diagnostic work-up with planned bone marrow assessments, or diagnosed with de novo or therapy-related MDS within 12 months of enrollment per the World Health Organization (WHO) criteria1 and undergoing clinical evaluation and planned bone marrow assessments to confirm MDS or to evaluate disease status
- Bone marrow aspirate expected to be performed within 1 week of registration, and in all cases must be performed no later than 4 weeks after enrollment
- Age 18 or older
- If anemic without prior MDS diagnosis, B12 level, serum folate, mean corpuscular volume (MCV), red cell distribution width (RDW), ferritin, and iron studies (Iron, total iron-binding capacity (TIBC) test, and percent saturation) must be performed within prior 6 months.
Who cannot join
- Prior treatment for MDS at entry and through the time of the entry bone marrow aspirate
- Treatment with hematopoietic growth factors in prior 6 months
- Diagnosis of a solid tumor or hematologic malignancy within two years prior to enrollment except for in situ cancer of the skin (basal or squamous cell), cervix, bladder, breast, or prostate
- Treatment with radiation therapy in the two years prior to registration
- Non-hormonal treatment for malignancy within the two years prior to registration
- Established hereditary bone marrow failure syndrome
- Known primary diagnosis of aplastic anemia, classical paroxysmal nocturnal hemoglobinuria, amegakaryocytic thrombocytopenic purpura, or large granular lymphocyte leukemia
- Enrolled in the Connect® MDS/AML Disease Registry (NCT01688011)
Trial locations and contacts
281 sites in 2 countries.
281 sites in 2 countries
United States280 sites
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Queen's Cancer Center - Pearlridge
‘Aiea, Hawaii, 96701
Avera Cancer Institute-Aberdeen
Aberdeen, South Dakota, 57401
Cleveland Clinic Akron General
Akron, Ohio, 44307
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Community Hospital of Anaconda
Anaconda, Montana, 59711
Kaiser Permanente-Anaheim
Anaheim, California, 92806
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Mission Hospital
Asheville, North Carolina, 28801
Northside Hospital
Atlanta, Georgia, 30342
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Augusta University Medical Center
Augusta, Georgia, 30912
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045
Dell Seton Medical Center at The University of Texas
Austin, Texas, 78701
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21231
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Waldo County General Hospital
Belfast, Maine, 04915
Kaiser Permanente-Bellflower
Bellflower, California, 90706
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889
Lehigh Valley Hospital-Muhlenberg
Bethlehem, Pennsylvania, 18017
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
Biddeford, Maine, 04005
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61704
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Ascension Southeast Wisconsin Hospital-Elmbrook Campus
Brookfield, Wisconsin, 53045
Maimonides Medical Center
Brooklyn, New York, 11219
Roswell Park Cancer Institute
Buffalo, New York, 14263
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, 48188
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62901
SIH Cancer Institute
Carterville, Illinois, 62918
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Centralia Oncology Clinic
Centralia, Illinois, 62801
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Ralph H Johnson VA Medical Center
Charleston, South Carolina, 29401
West Virginia University Charleston Division
Charleston, West Virginia, 25304
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
MetroHealth Medical Center
Cleveland, Ohio, 44109
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Mercy Hospital
Coon Rapids, Minnesota, 55433
Greater Regional Medical Center
Creston, Iowa, 50801
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Carle on Vermilion
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17821
Beaumont Hospital - Dearborn
Dearborn, Michigan, 48124
Atlanta VA Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital
Decatur, Illinois, 62522
Cancer Care Specialists of Central Illinois - Decatur
Decatur, Illinois, 62568
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50314
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Northside Hospital - Duluth
Duluth, Georgia, 30096
Saint Luke's Hospital of Duluth
Duluth, Minnesota, 55802
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Essentia Health Saint Mary's Medical Center
Duluth, Minnesota, 55805
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Durham VA Medical Center
Durham, North Carolina, 27705
Prisma Health Cancer Institute - Easley
Easley, South Carolina, 29640
Michigan State University Clinical Center
East Lansing, Michigan, 48824
Veterans Administration New Jersey Health Care System
East Orange, New Jersey, 07018-1095
Easton Hospital
Easton, Pennsylvania, 18042
Marshfield Medical Center - EC Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
AMITA Health Alexian Brothers Medical Center
Elk Grove Village, Illinois, 60007
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, 14905
Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
Cleveland Clinic Cancer Center/Fairview Hospital
Fairview, Ohio, 44111
Sanford Clinic North-Fargo
Fargo, North Dakota, 58102
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Augusta Health Center for Cancer and Blood Disorders
Fishersville, Virginia, 22939
Kaiser Permanente-Fontana
Fontana, California, 92335
Aurora Health Center-Fond du Lac
Fontana, Wisconsin, 54937
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Ascension Saint Francis-Reiman Cancer Center
Franklin, Wisconsin, 53132
Unity Hospital
Fridley, Minnesota, 55432
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia, 30501
Illinois CancerCare - Galesburg
Galesburg, Illinois, 61401
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Glens Falls Hospital
Glens Falls, New York, 12801
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare-Sletten Cancer Institute
Great Falls, Montana, 59406
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 53715
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Saint Francis Hospital
Greenville, South Carolina, 29601
Prisma Health System Cancer Institute - Eastside
Greenville, South Carolina, 29605
Prisma Health System Cancer Institute - Faris
Greenville, South Carolina, 29605
Saint Francis Cancer Center
Greenville, South Carolina, 29607
Self Regional Healthcare
Greenwood, South Carolina, 29646
Prisma Health System Cancer Institute - Greer
Greer, South Carolina, 29650
Kaiser Permanente - South Bay
Harbor City, California, 90710
Geisinger Medical Center - Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
AMITA Health Cancer Institute and Outpatient Center
Hinsdale, Illinois, 60521
Queen's Cancer Center - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii, 96817
OnCare Hawaii - Liliha
Honolulu, Hawaii, 96817
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Cleveland Clinic Cancer Center Independence
Independence, Ohio, 44131
Kaiser Permanente-Irvine
Irvine, California, 92618
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207
Mayo Clinic in Florida
Jacksonville, Florida, 32224
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
West Michigan Cancer Center
Kalamazoo, Michigan, 22787
Presence Saint Mary's Hospital
Kankakee, Illinois, 60901
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, 64128
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53412
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
North Shore University Hospital
Lake Success, New York, 11042
Northwell Health/Center for Advanced Medicine
Lake Success, New York, 11042
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida, 33805
Memorial Medical Center-Las Cruces
Las Cruces, New Mexico, 88011
OptumCare Cancer Care at Oakey
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
OptumCare Cancer Care at Mountainview
Las Vegas, Nevada, 89128
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Northside Hospital - Gwinnett
Lawrenceville, Georgia, 30046
Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, 73505
Sechler Family Cancer Center
Lebanon, Pennsylvania, 17042
Kansas Institute of Medicine Cancer and Blood Center
Lenexa, Kansas, 66219
Geisinger Medical Oncology - Lewisburg
Lewisburg, Pennsylvania, 17837
Cancer Center of Kansas - Liberal
Liberal, Kansas, 67901
Tibor Rubin VA Medical Center
Long Beach, California, 90822
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Kaiser Permanente-Cadillac
Los Angeles, California, 90034
William S Middleton VA Medical Center
Madison, Wisconsin, 53705
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54220
Cleveland Clinic Cancer Center Mansfield
Mansfield, Ohio, 44906
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
Vince Lombardi Cancer Clinic-Marinette
Marinette, Wisconsin, 54143
Marshfield Medical Center - Marshfield
Marshfield, Wisconsin, 54449
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, 53226
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Minneapolis VA Medical Center
Minneapolis, Minnesota, 55417
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Meharry Medical College
Nashville, Tennessee, 37208
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06511
Yale University
New Haven, Connecticut, 06520
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Regional Hematology and Oncology PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Stephens Memorial Hospital
Norway, Maine, 04268
Cancer Care Specialists of O'Fallon
O'Fallon, Illinois, 62269
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Ascension Mercy Hospital
Oshkosh, Wisconsin, 54904
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, 54904
Va Palo Alto Health Care System
Palo Alto, California, 94304
Kaiser Permanente - Panorama City
Panorama City, California, 91402
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Illinois CancerCare - Peoria
Peoria, Illinois, 61615
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
Phoenixville Hospital
Phoenixville, Pennsylvania, 19460
Kaiser Permanente Northwest
Portland, Oregon, 97227
Oregon Health & Science University
Portland, Oregon, 97239
Kootenai Cancer Center
Post Falls, Idaho, 83854
Pottstown Hospital
Pottstown, Pennsylvania, 19464
Geisinger Cancer Services - Pottsville
Pottsville, Pennsylvania, 17901
Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington, 98370
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
MultiCare Good Samaritan Hospital
Puyallup, Washington, 98372
Ascension All Saints Hospital
Racine, Wisconsin, 53405
Aurora Cancer Care-Racine
Racine, Wisconsin, 53406
Eisenhower Medical Center
Rancho Mirage, California, 92270
Monument Health Rapid City Hospital
Rapid City, South Dakota, 57701
Penn State Health Saint Joseph Medical Center
Reading, Pennsylvania, 19605
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Prisma Health System Cancer Institute - Butternut
Reidville, South Carolina, 29605
Marshfield Medical Center - Rice Lake
Rice Lake, Wisconsin, 54868
UT Southwestern Clinical Center at Richardson/Plano
Richardson, Texas, 75080
Kaiser Permanente-Riverside
Riverside, California, 92505
Penobscot Bay Medical Center
Rockport, Maine, 04856
Delbert Day Cancer Institute at PCRMC
Rolla, Missouri, 65401
Mercy Clinic - Rolla - Cancer and Hematology
Rolla, Missouri, 65401
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Ascension Saint Mary's Hospital
Saginaw, Michigan, 48601
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
Kaiser Permanente-San Diego Zion
San Diego, California, 92120
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
Kaiser Permanente-San Marcos
San Marcos, California, 92078
Kootenai Cancer Clinic
Sandpoint, Idaho, 83864
North Coast Cancer Care
Sandusky, Ohio, 44870
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
Sanford, Maine, 04073
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
Seattle Cancer Care Alliance
Seattle, Washington, 98109
University of Washington Medical Center
Seattle, Washington, 98115
Prisma Health System Cancer Institute - Seneca
Seneca, South Carolina, 29672
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55739
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin, 53081
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117
Phelps Memorial Hospital Center
Sleepy Hollow, New York, 10591
Suburban Hematology Oncology Associates - Snellville
Snellville, Georgia, 30078
Maine Medical Partners-South Portland
South Portland, Maine, 01406
Ascension Providence Hospitals - Southfield
Southfield, Michigan, 48075
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Prisma Health System Cancer Institute - Spartanburg
Spartanburg, South Carolina, 29307
Mercy Hospital Springfield
Springfield, Missouri, 65804
CoxHealth South Hospital
Springfield, Missouri, 65807
Marshfield Clinic Stevens Point Center
Stevens Point, Wisconsin, 54482
Aurora Medical Center in Summit
Summit, Wisconsin, 53066
MultiCare Tacoma General Hospital
Tacoma, Washington, 98405
Moffitt Cancer Center
Tampa, Florida, 33612
Montefiore Medical Center - Einstein Campus
The Bronx, New York, 10461
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467
James J Peters VA Medical Center
The Bronx, New York, 10468
William Beaumont Hospital - Troy
Troy, Michigan, 48073
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin, 54241
Carle Cancer Center
Urbana, Illinois, 61801
Indian River Medical Center
Vero Beach, Florida, 32960
Ascension Medical Group Southeast Wisconsin-Mayfair Road
Wauwatosa, Wisconsin, 53226
Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, 53226
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Aurora West Allis Medical Center
West Allis, Wisconsin, 53227
Mercy Medical Center-West Lakes
West Des Moines, Iowa, 50266
Veterans Affairs Connecticut Healthcare System-West Haven Campus
West Haven, Connecticut, 06516
Marshfield Clinic-Weston Center
Weston, Wisconsin, 54476
Associates In Womens Health
Wichita, Kansas, 67208
Cancer Center of Kansas - Wichita Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67208
Ascension Via Christi Hospitals Wichita
Wichita, Kansas, 67218
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
UPMC Susquehanna
Williamsport, Pennsylvania, 17701
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Inspira Medical Center Woodbury
Woodbury, New Jersey, 08096
Kaiser Permanente-Woodland Hills
Woodland Hills, California, 91367
Cleveland Clinic Wooster Family Health and Surgery Center
Wooster, Ohio, 44691
UMass Memorial Medical Center - University Campus
Worcester, Massachusetts, 01655
Metro Health Hospital
Wyoming, Michigan, 49519
WellSpan Health-York Hospital
York, Pennsylvania, 17401
York Hospital
York Village, Maine, 03909
IHA Hematology Oncology Consultants-Ann Arbor
Ypsilanti, Michigan, 48197
About this study
Official title: The National Myelodysplastic Syndromes Natural History Study
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Read the detailed description
Multi-center, prospective cohort study enrolling patients from centers in the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). The accrual period is 5+ years. After central pathology review of registered participants, approximately 2,000 cases of MDS or MDS/MPN overlap disorders, and 500 cases of ICUS will be identified for the longitudinal study cohort and up to 1000 cases will be identified for the cross-sectional cohort. No more than 3500 total participants will be registered. Participants in the longitudinal cohort may be followed for life.
The goal of the National MDS Study is to establish a publicly available resource to facilitate the study of MDS natural history. This will be accomplished through: 1) Creation of a multi-institutional, longitudinal collection of consistently processed and clinically well-annotated blood and tissue specimens collected prospectively from participants with MDS and participants with idiopathic cytopenia of undetermined significance (ICUS); and 2) Support for investigator-initiated studies of MDS that will have high-impact for MDS patients, including basic science, clinical, health outcomes and epidemiological research.
- Conditions
- Myelodysplastic Syndromes (MDS)
- Being tested
- Therapeutic
- Keywords
- National MDS Study, MDS, Idiopathic, cytopenia, cytopenias, ICUS, MDS/MPN, Myeloproliferative Neoplasm, Biorepository
- Medical subject headings
- Myelodysplastic Syndromes, Cytopenia, Myeloproliferative Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TherapeuticOther
Observational Study
| Study group | Role | What they receive |
|---|---|---|
| Longitudinal | Participants with MDS, MDS/MPN overlap disorder, AML <30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities Receives: Other: Therapeutic | |
| Cross-sectional | Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only Receives: Other: Therapeutic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients dying
Deaths will be reported on study case report forms
Measured: Through study completion, an average of 3 years
Secondary outcomes (1)
Number of participants progressing to Acute Myeloid Leukemia (AML)
Progression to AML will be reported on study case report forms
Measured: Through study completion, an average of 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 May 2016 (estimated)
- Study start13 Jun 2016
- Primary completion31 Jul 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Myelodysplastic Syndromes (MDS)Studies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,115 participants (actual)
- Target duration
- 9 Years
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Mikkael Sekeres, MD, MS, Study chair, University of MiamiAmy DeZern, MD, MHS, Study chair, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02775383
- Sponsor's protocol ID
- NHLBI-MDS
- Acronym
- MDS
- Status last verified
- Nov 2025
- First submitted
- 2 May 2016
- Last updated
- 3 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Gillis N, Colin-Leitzinger C, Tang YH, Otterstatter M, Sherman S, Zhang L, Moscinski LC, Walker ME, Painter JS, Abel GA, Al Baghdadi T, Deeg HJ, Foran JM, Gore SD, Harrington AM, Kroft SH, Liu JJ, Saber W, Virani S, Bejar R, Lindsley RC, Padron E, Walter MJ, Komrokji R, DeZern AE, Sekeres MA. Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex. Am J Hematol. 2026 Jun;101(6):1407-1420. doi: 10.1002/ajh.70279. Epub 2026 Mar 29.
PubMed 41906220DeZern AE, Gillis N, Otterstatter M, Abel G, Padron E, Deeg HJ, Al Baghdadi T, Liu J, Xie Z, Zhang L, Moscinski L, Kroft S, Harrington A, Foran J, Komrokji R, Starczynowski D, Gore S, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo N, Walter M, Sekeres MA. A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study. Blood Adv. 2026 Apr 28;10(8):2743-2753. doi: 10.1182/bloodadvances.2025018770.
PubMed 41671442Abel GA, Hebert D, Lee C, Rollison D, Gillis N, Komrokji R, Foran JM, Liu JJ, Al Baghdadi T, Deeg J, Gore S, Saber W, Wilson S, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023 Jul 25;7(14):3506-3515. doi: 10.1182/bloodadvances.2022009000.
PubMed 37146263DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023 Jul 25;7(14):3749-3759. doi: 10.1182/bloodadvances.2022008578.
PubMed 36947201
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The National Myelodysplastic Syndromes Natural History Study
- ClinicalTrials.gov ID
- NCT02775383
- Acronym / sponsor ID
- MDS / NHLBI-MDS
- Conditions
- Myelodysplastic Syndromes (MDS)
- Keywords
- National MDS Study, MDS, Idiopathic, cytopenia, cytopenias, ICUS, MDS/MPN, Myeloproliferative Neoplasm
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,115 participants (actual)
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 13 Jun 2016 (actual)
- Primary completion
- 31 Jul 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 17 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Detailed description
Multi-center, prospective cohort study enrolling patients from centers in the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). The accrual period is 5+ years. After central pathology review of registered participants, approximately 2,000 cases of MDS or MDS/MPN overlap disorders, and 500 cases of ICUS will be identified for the longitudinal study cohort and up to 1000 cases will be identified for the cross-sectional cohort. No more than 3500 total participants will be registered. Participants in the longitudinal cohort may be followed for life.
The goal of the National MDS Study is to establish a publicly available resource to facilitate the study of MDS natural history. This will be accomplished through: 1) Creation of a multi-institutional, longitudinal collection of consistently processed and clinically well-annotated blood and tissue specimens collected prospectively from participants with MDS and participants with idiopathic cytopenia of undetermined significance (ICUS); and 2) Support for investigator-initiated studies of MDS that will have high-impact for MDS patients, including basic science, clinical, health outcomes and epidemiological research.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 9 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Longitudinal | – | Other: TherapeuticParticipants with MDS, MDS/MPN overlap disorder, AML <30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities |
| Cross-sectional | – | Other: TherapeuticParticipants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with suspected MDS or MDS/MPN overlap disorder who are undergoing diagnostic workup and bone marrow assessments, and patients diagnosed with MDS within 6-months of enrollment and undergoing clinical evaluation and bone marrow assessments to confirm MDS or evaluate disease status
Key inclusion criteria (4 listed)
- Suspected (e.g., persistent unexplained cytopenia, circulating peripheral blasts etc.) MDS or MDS/MPN overlap disorders and undergoing diagnostic work-up with planned bone marrow assessments, or diagnosed with de novo or therapy-related MDS within 12 months of enrollment per the World Health Organization (WHO) criteria1 and undergoing clinical evaluation and planned bone marrow assessments to confirm MDS or to evaluate disease status
- Bone marrow aspirate expected to be performed within 1 week of registration, and in all cases must be performed no later than 4 weeks after enrollment
- Age 18 or older
- If anemic without prior MDS diagnosis, B12 level, serum folate, mean corpuscular volume (MCV), red cell distribution width (RDW), ferritin, and iron studies (Iron, total iron-binding capacity (TIBC) test, and percent saturation) must be performed within prior 6 months.
Key exclusion criteria (8 listed)
- Prior treatment for MDS at entry and through the time of the entry bone marrow aspirate
- Treatment with hematopoietic growth factors in prior 6 months
- Diagnosis of a solid tumor or hematologic malignancy within two years prior to enrollment except for in situ cancer of the skin (basal or squamous cell), cervix, bladder, breast, or prostate
- Treatment with radiation therapy in the two years prior to registration
- Non-hormonal treatment for malignancy within the two years prior to registration
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TherapeuticObservational Study | Other | Cross-sectional, Longitudinal |
Primary outcome
Number of patients dying
Time frame: Through study completion, an average of 3 years
Deaths will be reported on study case report forms
1 secondary outcome
Number of participants progressing to Acute Myeloid Leukemia (AML)
Time frame: Through study completion, an average of 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2026.
- Derived from this study: PubMed 41906220Gillis N, Colin-Leitzinger C, Tang YH, Otterstatter M, Sherman S, Zhang L, Moscinski LC, Walker ME, Painter JS, Abel GA, Al Baghdadi T, Deeg HJ, Foran JM, Gore SD, Harrington AM, Kroft SH, Liu JJ, Saber W, Virani S, Bejar R, Lindsley RC, Padron E, Walter MJ, Komrokji R, DeZern AE, Sekeres MA. Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex. Am J Hematol. 2026 Jun;101(6):1407-1420. doi: 10.1002/ajh.70279. Epub 2026 Mar 29.
- Derived from this study: PubMed 41671442DeZern AE, Gillis N, Otterstatter M, Abel G, Padron E, Deeg HJ, Al Baghdadi T, Liu J, Xie Z, Zhang L, Moscinski L, Kroft S, Harrington A, Foran J, Komrokji R, Starczynowski D, Gore S, Saber W, Bejar R, Lindsley RC, Sherman S, Lee C, DiFronzo N, Walter M, Sekeres MA. A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study. Blood Adv. 2026 Apr 28;10(8):2743-2753. doi: 10.1182/bloodadvances.2025018770.
- Derived from this study: PubMed 37146263Abel GA, Hebert D, Lee C, Rollison D, Gillis N, Komrokji R, Foran JM, Liu JJ, Al Baghdadi T, Deeg J, Gore S, Saber W, Wilson S, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023 Jul 25;7(14):3506-3515. doi: 10.1182/bloodadvances.2022009000.
- Derived from this study: PubMed 36947201DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023 Jul 25;7(14):3749-3759. doi: 10.1182/bloodadvances.2022008578.
- Website for The National Myelodysplastic Syndromes Natural History StudyLink provided by the sponsor.
Related trials for Myelodysplastic Syndromes (MDS)
Active, not recruitingPhase 2
Cord Blood Transplant in Adults With Blood Cancers
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Enrolling by invitationObservational study
Biology Studies of Hematologic Cancers
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Enrolling by invitationObservational study
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
RecruitingPhase 1
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
AML/MDS, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mikkael Sekeres, MD, MS study chair
University of Miami
Amy DeZern, MD, MHS study chair
Johns Hopkins University
281 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myelodysplastic Syndromes (MDS), run by National Heart, Lung, and Blood Institute (NHLBI) at 281 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 281 sites in United States, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients dying (time frame: Through study completion, an average of 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02775383, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026; AzTrials last refreshed its copy on 26 Oct 2026.